Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

DKFZ proposal nominated as first funded project of beLAB2122

No. 56c | 27/10/2021 | by Koh

To translate results from academic research in the Rhine-Main-Neckar life science region, the drug discovery and development company Evotec, in collaboration with Bristol Myers Squibb, recently launched the "beLAB2122" research network. The German Cancer Research Center (DKFZ) as one of the academic partners of the new BRIDGE academic partnership. Evotec has now selected a DKFZ project for initial funding.

beLAB2122: A new bridge connects research and industry
© Wikimedia Commons

Following the signing of the beLAB2122 collaboration agreement in April 2021, Evotec has now nominated the first project to be developed under this academic BRIDGE partnership.

The project, planned in the laboratory of Darjus Tschaharganeh at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), involves the development of compounds that target cancer cells on the basis of so-called "synthetic lethality". Scientists speak of synthetic lethal interactions between two genes when a cell is viable when one of these two genes is disrupted, but the disruption of both genes at the same time leads to a loss of viability. „Our project aims to develop small-molecular inhibitors of a nutrient transporter important for the survival of certain cancer cells. beLAB2122 provides the fantastic opportunity to use Evotec's integrated research and development platform to validate and further develop our project with the goal to advance it to a point where new, jointly operated spin-off company with BMS can be formed, said Tschaharganeh, group leader at the DKFZ, and Professor at Heidelberg University.

beLAB2122 will now use Evotec's integrated research and development platform to validate and further develop the project. The goal of beLAB2122 is to advance academic projects to a point where new, jointly operated spin-off companies can be formed.

beLAB2122 brings together the leading academic institutions from the Rhine-Main-Neckar region to efficiently translate promising treatment approaches in all therapeutic areas and formats into investable drug discovery and early development projects.

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS